Literature DB >> 3943010

Treatment of polycythemia vera with hydroxyurea.

R Sharon, I Tatarsky, Y Ben-Arieh.   

Abstract

Thirty-six patients with polycythemia vera were treated with hydroxyurea for 12 to 67 months. Nineteen patients were previously treated with other drugs. In the vast majority of patients, an average dose of 1 g/day was sufficient to control hematocrit value and platelet count. Half of the patients experienced relief of pruritus, and two thirds experienced regression of splenomegaly. None of the patients had either thrombotic complications or leukemia. Four patients suffered from mild side effects, which included fever, hyperbilirubinemia, and stomatitis, and were relieved of their symptoms when treatment was stopped. However, two patients experienced renal failure, a possible major complication not described previously.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943010     DOI: 10.1002/1097-0142(19860215)57:4<718::aid-cncr2820570406>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

Review 1.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

2.  Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.

Authors:  Despina Mavrogianni; Nora Viniou; Evi Michali; Evangelos Terpos; John Meletis; George Vaiopoulos; Marina Madzourani; Gerasimos Pangalis; Xenophon Yataganas; Dimitris Loukopoulos
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

3.  A phase I trial of high-dose continuous-infusion hydroxyurea.

Authors:  D C Smith; W P Vaughan; P R Gwilt; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

Authors:  Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison
Journal:  Br J Haematol       Date:  2018-11-13       Impact factor: 6.998

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.